Testing a dye to help surgeons see solid tumor edges
Tests indocyanine green dye imaging to help mark solid tumor edges during surgery in adults.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Rotterdam, NetherlandsSee the site
- Trial code
- Registry title
- The Surf trial
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 40 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid cancer who will have surgery to remove it. It tests a fluorescent dye called ICG that may show the tumor edges.
- Age
- 18 years or older
- Sex
- Women and men can both join
- Disease stage
- Solid cancer confirmed by tissue examination (for example head and neck, gut, liver and bile ducts, breast, urinary and genital organs, sarcoma). Surgery must be planned to remove all of the disease.
Main reasons for not taking part
- Known allergy to Indocyanine Green (ICG), iodine or shellfish
- Pregnant or breastfeeding
- Significant kidney problems (eGFR <50 mL/min/1.73 m²)
- Overactive thyroid or other active thyroid disease
- Any condition the investigator thinks puts the person at undue risk or disturbs the study
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age ≥18 years
- Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)
- Candidate for surgical resection with curative intent
- Ability to provide written informed consent
- Adequate organ function to undergo surgery and ICG administration
Who cannot take part
- Known allergy to Indocyanine Green (ICG), iodine, or shellfish
- Hyperthyroidism or other active thyroid disease
- Any condition deemed by the investigator to place the patient at undue risk or interfere with study procedures
- Significant renal impairment (eGFR <50 mL/min/1.73 m²)
- Pregnant or breastfeeding
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To determine the optimal dose and timing of intravenous ICG to achieve sufficient tumor-to background contrast in solid tumors and to evaluate whether ICG fluorescence imaging can accurately identify tumor margins during surgery.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green
- Plain-language title
- Testing a dye to help surgeons see solid tumor edgesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 April 2026